Russell Investments Group Ltd. Takes Position in Inhibrx, Inc. (NASDAQ:INBX)

Russell Investments Group Ltd. acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,345 shares of the company's stock, valued at approximately $837,000. Russell Investments Group Ltd. owned 0.38% of Inhibrx as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Exchange Traded Concepts LLC acquired a new stake in shares of Inhibrx in the fourth quarter valued at about $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Inhibrx during the 4th quarter worth approximately $348,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inhibrx in the 4th quarter worth approximately $47,000. Rhumbline Advisers bought a new stake in shares of Inhibrx in the 4th quarter valued at $228,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Inhibrx during the fourth quarter worth $53,000. 82.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Stock Up 2.3 %

NASDAQ:INBX traded up $0.28 on Friday, hitting $12.26. The stock had a trading volume of 41,757 shares, compared to its average volume of 197,947. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $34.75. The business's fifty day moving average is $13.01 and its 200 day moving average is $14.07.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. As a group, research analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.